Detection of AD Biomarkers in Tear Fluid (SmartTears)

Maastricht University Medical Centre (MUMC)

Status: Completed

Conditions: Cognitive Impairment

Treatments: Other: Tear sampling

Study type: Observational

Funder types: Other

Identifiers

NCT04620902

15-4-100

Details and patient eligibility

About

Detection of AD biomarkers in tear fluid

Enrollment: 69 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• . Inclusion criteria were an MMSE score ≥ 20 and a CDR score from 0 to 1, thereby including patients across the whole clinical spectrum (i.e. from subjective cognitive disorder to (mild) dementia).

Exclusion criteria

• Exclusion criteria at baseline were neurological diseases (such as Normal Pressure Hydrocephalus, Morbus Huntington, brain tumor, epilepsy, encephalitis, recent Transient Ischemic Attack (TIA) or cerebrovascular accident (CVA) (< 2 years), or TIA/CVA with concurrent (within three months) cognitive decline) and a history of psychiatric disorders (such as schizophrenia, bipolar disorder or psychotic problems, current major depressive disorder (within 12 months), or alcohol abuse).

Trial design

69 participants in 4 patient groups

Dementia

Description:

Dementia

Treatment:

Other: Tear sampling

MCI

Description:

Mild cognitive impairment

Treatment:

Other: Tear sampling

SCD

Description:

Subjective cognitive decline

Treatment:

Other: Tear sampling

HC

Description:

Cognitively healthy control

Treatment:

Other: Tear sampling